ELOS B

Elos Medtech

Market Cap 577.7M

Elos Medtech har en historik som sträcker sig mer än 90 år tillbaka och bolaget har bedrivit vitt skilda verksamheter. Bolaget som börsnoterades 1989 hette då Westergyllen och 2006 knoppades bolaget som nu heter Götenehus av. Det var dock så sent som våren 2015 som Elos blev Elos Medtech för att markera renodlingen till medtechbolag. Det första steget mot medicinsk teknik var förvärvet av Elos Medtech i Timmersdala. Det danska bolaget Pinol köptes 2005 och sedan dess har bolaget under en tioårsperiod transformerats till dagens renodlade medtech bolag genom att köpa verksamhet inom medtech och sälja övrig verksamhet. Elos Medtech hade i slutet av 2016 511 anställda i framför allt Danmark, Sverige, USA och Kina. Omsättningen under 2016 var 552 miljoner kronor.

+ more

Redeye Research

Reports

Notes

Today
Day High
70.80
70.8
Day Low
70.00
Day Open
70.80
Prev Close
71.60
VWAP
70.3
Volume
0K
Turnover
0.005M
Top Broker
ENS
VWAP
72.5
Avg Volume
10K
Avg Turnover
0.748M
Top Brokers
NON/AVA
VWAP
72.3
Avg Volume
6K
Avg Turnover
0.456M
Top Brokers
NON/AVA
VWAP
72.2
Avg Volume
4K
Avg Turnover
0.297M
Top Brokers
NON/AVA
52 week summary
Price Range
55.3
Last
84.1
Beta
N/A
Market Cap
577.7M
Total Return
-7.9%
Trailing P/E
21.3
Div Yield
0.0%
Shares Outstanding
8.1M
Stock Exchange
NASDAQ Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months 5.5%
Change 12 Months -7.8%
Volume Trend
Average Volume 10 vs 60 Days 60.4%
Price VS
52 Week High -15.8%
50 Day Moving Average -1.4%
200 Day moving Average 2.6%

Add article markers

Compare Elos Medtech to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
Last updated: 2017-04-27 Source: Redeye
Major Owners Equity Votes
Nordea Fonder 13.9%
6.2%
Svolder 11.5%
5.2%
Familjen Öster inkl bolag 10.9%
23.6%
Familjen Runmarker 6.4%
17.8%
Familjen Nilsson 5.3%
15.4%
Familjen Molin 5.0%
9.0%
Healthinvest Partners AB 4.7%
2.1%
Magledal Holding APS 3.0%
1.3%
Eccenovo AB 2.2%
0.8%
Ulrika Erlandsson 1.6%
2.0%
Last updated: 2018-05-29 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
1 Purchases
20,000
0 Sales
0
Last 24 weeks
1 Purchases
20,000
0 Sales
0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Insider trades are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2015
  •  
  • 4.8%
  • 5.3%
  • 5.9%
  • 15.7%
  • 6.1%
  • 3.2%
  •  
  • 2.66
  • 2.66
  • 1.00
  •  
  • 6.1
  •  
  • 1,009.7
  • 45.1
  • 45.1
  • 1.4
  • 2.0
  • 12.7
  • 33.1
  • 2.2
  •  
  • 37.5%
  • 30.9%
  • 284
  • 614
  • 0.6
  • 2015
  •  
  •  
  • 41
  • 59
  • 130
  • 10
  • 239
  •  
  • 357
  • 0
  • 1
  • 235
  • 0
  • 41
  • 0
  • 633
  • 9
  • 882
  •  
  •  
  • 83
  • 137
  • 0
  • 220
  • 241
  • 0
  • 0
  • 461
  • 23
  • 67
  • 331
  • 0
  • 331
  • 882
  • 2015
  • 504
  • -424
  • -49
  • 31
  • -9
  • 22
  • 49
  • 71
  • 55
  • -144
  • -146
  • 2015 Q2
  • 139
  • -111
  • 28
  • -12
  • 0
  • 0
  • 16
  • 0
  • -5
  • 0
  • 11
  • -3
  • 8
  • 2015 Q3
  • 123
  • -105
  • 18
  • -14
  • 0
  • 0
  • 4
  • 0
  • -3
  • 0
  • 1
  • -2
  • 0
  • 2015 Q4
  • 136
  • -118
  • 18
  • -13
  • 0
  • 0
  • 5
  • 0
  • -3
  • 0
  • 3
  • 1
  • 3
  • 2016
  •  
  • 7.6%
  • 7.0%
  • 4.9%
  • 17.6%
  • 7.7%
  • 4.8%
  •  
  • 4.38
  • 4.38
  • 1.30
  •  
  • 6.1
  •  
  • 935.1
  • 23.5
  • 23.5
  • 1.1
  • 1.7
  • 9.6
  • 21.9
  • 1.7
  •  
  • 41.3%
  • 36.1%
  • 313
  • 680
  • 0.6
  • 2016
  •  
  •  
  • 38
  • 61
  • 131
  • 5
  • 236
  •  
  • 354
  • 0
  • 1
  • 254
  • 0
  • 36
  • 0
  • 646
  • 6
  • 888
  •  
  •  
  • 128
  • 109
  • 0
  • 238
  • 223
  • 0
  • 0
  • 461
  • 31
  • 29
  • 367
  • 0
  • 367
  • 888
  • 2016
  • 552
  • -455
  • -55
  • 43
  • -13
  • 30
  • 55
  • 84
  • -27
  • 7
  • -40
  • 2016 Q1
  • 140
  • -115
  • 25
  • -13
  • 0
  • 0
  • 12
  • 0
  • -5
  • 0
  • 7
  • -2
  • 5
  • 2016 Q2
  • 152
  • -122
  • 29
  • -13
  • 0
  • 0
  • 16
  • 0
  • -2
  • 0
  • 15
  • -4
  • 10
  • 2016 Q3
  • 127
  • -101
  • 25
  • -14
  • 0
  • 0
  • 12
  • 0
  • -1
  • 0
  • 11
  • -2
  • 9
  • 2016 Q4
  • 133
  • -116
  • 17
  • -14
  • 0
  • 0
  • 3
  • 0
  • 3
  • 0
  • 6
  • -3
  • 3
  • 2017
  •  
  • 6.1%
  • 5.1%
  • 5.4%
  • 16.3%
  • 7.4%
  • 3.9%
  •  
  • 3.73
  • 3.73
  • 0.00
  •  
  • 6.1
  •  
  • 680.7
  • 16.3
  • 16.3
  • 0.6
  • 1.2
  • 7.2
  • 15.9
  • 1.0
  •  
  • 43.5%
  • 46.6%
  • 312
  • 681
  • 0.7
  • 2017
  •  
  •  
  • 10
  • 78
  • 142
  • 7
  • 237
  •  
  • 335
  • 0
  • 0
  • 235
  • 0
  • 32
  • 0
  • 602
  • 8
  • 848
  •  
  •  
  • 116
  • 87
  • 0
  • 202
  • 206
  • 0
  • 0
  • 408
  • 33
  • 37
  • 369
  • 0
  • 369
  • 848
  • 2017
  • 578
  • -484
  • -51
  • 43
  • -6
  • 37
  • 51
  • 88
  • -53
  • 24
  • 67
  • 2017 Q1
  • 141
  • -114
  • 27
  • -14
  • 0
  • 0
  • 13
  • 0
  • -4
  • 0
  • 10
  • -2
  • 7
  • 2017 Q2
  • 156
  • -129
  • 27
  • -13
  • 0
  • 0
  • 14
  • 0
  • -8
  • 0
  • 6
  • -1
  • 5
  • 2017 Q3
  • 133
  • -110
  • 22
  • -13
  • 0
  • 0
  • 9
  • 0
  • -4
  • 0
  • 5
  • -2
  • 3
  • 2017 Q4
  • 149
  • -130
  • 19
  • -12
  • 0
  • 0
  • 7
  • 0
  • -1
  • 0
  • 6
  • 2
  • 8
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 Q1
  • 156
  • -131
  • 25
  • -14
  • 0
  • 0
  • 11
  • 0
  • -2
  • 0
  • 9
  • -3
  • 6
  • 2018 Q2 E
  • 2018 Q3 E
  • 2018 Q4 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 Q1 E
  • 2019 Q2 E
  • 2019 Q3 E
  • 2019 Q4 E
  • 2020 E
  • 2020 E
  • 2020 E
  • 2020 Q1 E
  • 2020 Q2 E

Estimated Values are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2018-05-29 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.